Europe Monoclonal Antibodies Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

No. of Pages: 172    |    Report Code: TIPRE00027983    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Monoclonal Antibodies Market
Free Sample Buy Now

1.           Introduction

1.1         Study Scope

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Europe Monoclonal Antibodies (mAbs) Market – By Source

1.3.2        Europe Monoclonal Antibodies (mAbs) Market – By Production Method

1.3.3        Europe Monoclonal Antibodies (mAbs) Market – By Indication

1.3.4        Europe Monoclonal Antibodies (mAbs) Market – By Application

1.3.5        Europe Monoclonal Antibodies (mAbs) Market – By End-User

1.3.6        Europe Monoclonal Antibodies (mAbs) Market – By Geography

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Monoclonal Antibodies (mAbs) Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Europe PEST Analysis

4.3         Experts Opinion

5.           Monoclonal Antibodies (mAbs) Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of Cancer and Other Chronic Diseases

5.1.2        mABs Uptake Proves to be Effective During Pandemic Outbreak

5.2         Market Restraints

5.2.1        Low Awareness, Accessibility, and High Cost

5.3         Market Opportunities

5.3.1        Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity

5.4         Future Trends

5.4.1        Strategic Research Collaborations

5.5         Impact Analysis

6.           Monoclonal Antibodies (mAbs) Market– Europe Analysis

6.1         Europe Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis

7.           Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source

7.1         Overview

7.2         Europe Monoclonal Antibodies (mAbs) Market, By Source, 2020 & 2028 (%)

7.3         Murine

7.3.1        Overview

7.3.2        Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.4         Chimeric

7.4.1        Overview

7.4.2        Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.5         Humanized

7.5.1        Overview

7.5.2        Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.6         Human

7.6.1        Overview

7.6.2        Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

8.           Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method

8.1         Overview

8.2         Europe Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)

8.3         In-Vivo

8.3.1        Overview

8.3.2        In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

8.4         In-Vitro

8.4.1        Overview

8.4.2        In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.           Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication

9.1         Overview

9.2         Europe Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)

9.3         Cancer

9.3.1        Overview

9.3.2        Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.4         Autoimmune Diseases

9.4.1        Overview

9.4.2        Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.5         Inflammatory Diseases

9.5.1        Overview

9.5.2        Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.6         Infectious Diseases

9.6.1        Overview

9.6.2        Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.7         Microbial Diseases

9.7.1        Overview

9.7.2        Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.8         Others

9.8.1        Overview

9.8.2        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application

10.1      Overview

10.2      Europe Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)

10.3      Diagnostic Applications

10.3.1     Overview

10.3.2     Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.4      Therapeutic Applications

10.4.1     Overview

10.4.2     Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.5      Research Applications

10.5.1     Overview

10.5.2     Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User

11.1      Overview

11.2      Europe Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)

11.3      Hospitals

11.3.1     Overview

11.3.2     Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.4      Research Institutes

11.4.1     Overview

11.4.2     Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.5      Others

11.5.1     Overview

11.5.2     Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

12.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis

12.1      Europe: Monoclonal Antibodies (mAbs) Market

12.1.1     Overview

12.1.2     Europe: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.3     Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.1.4     Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.5     Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.1.6     Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.1.7     Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.1.8     Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

12.1.8.1       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.1.1       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.1.2       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.1.8.1.3       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.8.1.4       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.1.8.1.5       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.1.8.1.6       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product (US$ Mn)

12.1.8.1.7       Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.1.8.2       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.2.1       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.2.2       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.1.8.2.3       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.8.2.4       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.1.8.2.5       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.1.8.2.6       UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Mn)

12.1.8.3       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.3.1       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.3.2       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.1.8.3.3       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.8.3.4       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.1.8.3.5       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.1.8.3.6       France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.1.8.4       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.4.1       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.4.2       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.1.8.4.3       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.8.4.4       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.1.8.4.5       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.1.8.4.6       Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.1.8.5       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.5.1       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.5.2       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.1.8.5.3       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.8.5.4       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.1.8.5.5       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.1.8.5.6       Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.1.8.6       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.6.1       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.1.8.6.2       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source(US$ Mn)

12.1.8.6.3       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.1.8.6.4       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication(US$ Mn)

12.1.8.6.5       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application(US$ Mn)

12.1.8.6.6       Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

13.        Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market

13.1      Europe: Impact Assessment of COVID-19 Pandemic

14.        Monoclonal Antibodies (mAbs) Market–Industry Landscape

14.1      Overview

14.2      Growth Strategies Done by the Companies in the Market, (%)

14.3      Organic Developments

14.3.1     Overview

14.4      Inorganic Developments

14.4.1     Overview

15.        Company Profiles

15.1      Novartis AG

15.1.1     Key Facts

15.1.2     Business Description

15.1.3     Products and Services

15.1.4     Financial Overview

15.1.5     SWOT Analysis

15.1.6     Key Developments

15.2      Pfizer Inc.

15.2.1     Key Facts

15.2.2     Business Description

15.2.3     Products and Services

15.2.4     Financial Overview

15.2.5     SWOT Analysis

15.2.6     Key Developments

15.3      GlaxoSmithKline plc.

15.3.1     Key Facts

15.3.2     Business Description

15.3.3     Products and Services

15.3.4     Financial Overview

15.3.5     SWOT Analysis

15.3.6     Key Developments

15.4      Amgen Inc.

15.4.1     Key Facts

15.4.2     Business Description

15.4.3     Products and Services

15.4.4     Financial Overview

15.4.5     SWOT Analysis

15.4.6     Key Developments

15.5      DAIICHI SANKYO COMPANY LIMITED

15.5.1     Key Facts

15.5.2     Business Description

15.5.3     Products and Services

15.5.4     Financial Overview

15.5.5     SWOT Analysis

15.5.6     Key Developments

15.6      F. HOFFMANN-LA ROCHE LTD.

15.6.1     Key Facts

15.6.2     Business Description

15.6.3     Products and Services

15.6.4     Financial Overview

15.6.5     SWOT Analysis

15.6.6     Key Developments

15.7      AstraZeneca

15.7.1     Key Facts

15.7.2     Business Description

15.7.3     Products and Services

15.7.4     Financial Overview

15.7.5     SWOT Analysis

15.7.6     Key Developments

15.8      Eli Lilly and Company.

15.8.1     Key Facts

15.8.2     Business Description

15.8.3     Products and Services

15.8.4     Financial Overview

15.8.5     SWOT Analysis

15.8.6     Key Developments

15.9      Bayer AG

15.9.1     Key Facts

15.9.2     Business Description

15.9.3     Products and Services

15.9.4     Financial Overview

15.9.5     SWOT Analysis

15.9.6     Key Developments

15.10   Bristol-Myers Squibb Company

15.10.1  Key Facts

15.10.2  Business Description

15.10.3  Products and Services

15.10.4  Financial Overview

15.10.5  SWOT Analysis

15.10.6  Key Developments

16.        Appendix

16.1      About The Insight Partners

16.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn).

Table 2.             Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method  (US$ Mn).

Table 3.             Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn).

Table 4.             Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn).

Table 5.             Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 6.             Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 7.             Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 8.             Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 9.             Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 10.          Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product US$ Mn)

Table 11.          Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 12.          UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 13.          UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 14.          UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 15.          UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 16.          UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Mn)

Table 17.          France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 18.          France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 19.          France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 20.          France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 21.          France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 22.          Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 23.          Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 24.          Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 25.          Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 26.          Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 27.          Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 28.          Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 29.          Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 30.          Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 31.          Spain Monoclonal Antibodies (mAbs) Market, by End User – Revenue and Forecast to 2028 by End User (USD Million)

Table 32.          Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 33.          Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 34.          Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 35.          Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 36.          Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 37.          Organic Developments Done by Companies

Table 38.          Inorganic Developments Done by Companies

Table 39.          Glossary of Terms

 


LIST OF FIGURES

Figure 1.           Monoclonal Antibodies (mAbs) Market Segmentation

Figure 2.           Europe Monoclonal Antibodies (mAbs) Market Overview

Figure 3.           Human Segment Held Largest Share of Source Segment in Monoclonal Antibodies (mAbs) Market

Figure 4.           UK is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           Europe Monoclonal Antibodies (mAbs) Market, Industry Landscape

Figure 6.           Europe: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market

Figure 9.           Europe Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028

Figure 10.        Europe Monoclonal Antibodies (mAbs) Market, by Source, 2020 & 2028 (%)

Figure 11.        Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12.        Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 14.        Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 15.        Europe Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)

Figure 16.        In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 17.        In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 18.        Europe Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)

Figure 19.        Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 20.        Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 21.        Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 22.        Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 23.        Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 24.        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 25.        Europe Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)

Figure 26.        Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 27.        Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 28.        Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 29.        Europe Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)

Figure 30.        Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 31.        Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 32.        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 33.        Europe: Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ MN)

Figure 34.        Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 35.        Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

Figure 36.        Impact of COVID-19 Pandemic in European Country Markets

Figure 37.        Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Europe Monoclonal Antibodies Market

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc.
  4. Amgen Inc
  5. DAIICHI SANKYO COMPANY, LIMITED
  6. F. Hoffmann-La Roche Ltd.
  7. AstraZeneca
  8. Eli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company
europe-monoclonal-antibodies-market